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a  b s  t r a  c t
Parathormone plays a  key role in controlling mineral metabolism. PTH is considered a ure-
mic  toxin  causing cardiovascular damage and cardiovascular mortality in dialysis patients.
There  are two different assays to measure PTH called 2nd generation or intact PTH (iPTH)
and  3rd generation or bioPTH (PTHbio).
Objective: To evaluate the differences in mortality of dialysis patients between both assays
to measure PTH, as  well as  the possible prognostic role of the PTHbio/iPTH ratio.
Methods:  145 haemodialysis patients were included with 2-year monitoring including base-
line  laboratory test and annually thereafter.
Results: 21  patients died in the first year and 28 in the  second. No correlation was found
between PTH, PTHbio and PTHbio/iPTH ratio with mortality. Both PTH have a  perfect correla-
tion between them and correlate similarly with other molecules of the mineral metabolism.
The extreme baseline values of PTH are those of higher mortality. In survival by iPTH inter-
vals (according to guidelines and COSMOS study), a  J  curve is observed. When iPTH increases,
the  ratio decreases, possibly when increasing fragments no. 1–84. There is no greater
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prognostic approximation on mortality with PTHbio than PTHi. There was also no difference
in mortality when progression ratio PTHbio/PTHi was analysed.
Conclusions: We  didn’t find any advantages to using bioPTH vs. PTHi as  a  marker of mortality.
BioPTH limits of normality must be reevaluated because its relationship with iPTH is not
consistent. Not knowing these limits affects its  prognostic value.
©  2017 Sociedad Espan˜ola de  Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Diferencias  entre  los  métodos  de determinación  de 2.a y 3.a generación  de
la  parathormona  sérica sobre  la  mortalidad  en  el paciente  en  hemodiálisis
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Cardiovascular
r  e s u m  e n
La paratohormona tiene un  papel fundamental en el control del metabolismo mineral.
Además  es considerada como una toxina urémica al originar dan˜o cardiovascular e influir
en la mortalidad cardiovascular del paciente en diálisis. Existen dos métodos de medición
denominados de 2.a generación o PTH intacta (PTHi) y de 3.a generación o bioPTH (PTHbio).
Objetivo: Evaluar las diferencias en la mortalidad del paciente en diálisis entre ambas formas
de  medición de PTH, así como el posible papel pronóstico de  su cociente.
Métodos: Se incluyeron 145 pacientes en hemodiálisis con un seguimiento de 2 an˜os con
determinación analítica basal y  posteriormente de forma anual.
Resultados: Veintiún pacientes fallecieron el primer an˜o y  28 el  segundo. No se encontró
correlación entre PTHi, PTHbio y  cociente PTHbio/PTHi con la mortalidad. Ambas PTH tienen
una  buena correlación entre ellas y  correlacionan de manera similar con otras moléculas del
metabolismo mineral. Los valores basales de  PTH extremos son los de mayor mortalidad.
En  la supervivencia por tramos de PTHi (según guías y  estudio COSMOS) se observa una
curva en J. A  mayor aumento de PTHi  el cociente desciende, posiblemente al aumentar los
fragmentos no 1-84. No existe una mayor aproximación pronóstica sobre mortalidad con
PTHbio que con PTHi. No se observan diferencias en el valor predictivo del cociente sobre la
mortalidad. Tampoco hubo diferencias en mortalidad cuando se analiza la progresión del
cociente PTHbio/PTHi.
Conclusiones: No encontramos ventajas en la utilización de PTHbio sobre la PTHi como mar-
cador de mortalidad. Se deben reevaluar los límites de  la PTHbio pues su relación con la
PTHi  no es  constante. El no conocer esos límites condiciona su utilidad pronóstica.
©  2017 Sociedad Espan˜ola de  Nefrologı´a. Publicado por  Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
The Parathyroid Hormone (PTH) is a 84 amino acids pro-
tein with a established role in  the regulation of mineral
metabolism; main target organs are the bone and kidneys
among others. In spite of being a  hormone, in the case of the
renal patient, it is classified as a true uremic toxin because
it increases progressively with the progression chronic kid-
ney disease (CKD), and it responsible for  multiple systemic
effects.1,2 It  is included as one of the uremic toxins that cause
cardiovascular damage.3,4
The control of PTH is important for the adequate treat-
ment of the abnormalities of mineral metabolism in CKD.
Therefore much of the therapeutic efforts aimed at control-
ling these alterations are dedicated to an  adequate control
of PTH. Nevertheless, in hemodialysis patients PTH is  a poor
marker of mortality. Only large studies have revealed that
high PTH values that are related to higher mortality. And
in these studies the results are variable.4–8 However, other
molecules such as calcium and phosphorus have shown a
better prognostic significance on mortality, along with vita-
min D, although with the later the results have been less
conclusive.9,10
Circulating PTH includes a  mixture of peptides such as
the whole molecule 1–84 and smaller fragments resulting
from the  catabolism of PTH, these are called non-1–84 or car-
boxyterminal fragments. Only PTH 1–84 (whole protein) exert
biological activity. Some of the carboxyterminal fragments
have a PTH antagonistic action. PTH is  cleared by the kidney
and the proportion of these PTH peptides varies according to
the CKD stage. The methods currently used to measure PTH
in clinical practice are of two categories. The so-called 2nd
generation that measures the intact 1–84 PTH (PTHi) and mul-
titude of fragments no 1–84.  The 3rd generation method, also
called PTHbio, recently marketed, quantify the PTH 1–84 only,
although its use is  not generalized yet.11,12
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In an attempt to integrate the information provided bay
the measurement of both molecules, some authors have advo-
cated the utility of the proportion (ratio) of these molecules by
the ratio PTHbio/PTHi as  a  marker of the bone remodeling13,14
and mortality.15
In clinical practice, there are currently two criteria to
define the normal values of PTH. The first, and most clas-
sic, is based on histomorphometry as defined by the Guides
KDOQI16 and the Guidelines SEN.17 At that time, based on
bone biopsies, bone abnormalities were present if  PTHi was
lower than150 pg/ml or  above 300 pg/ml. The range of normal-
ity were established according to relationship of iPTH with
the lesions observed in  the bone biopsy.18 These values still
exist in most of the recommendations. The other criterion is
mortality. There are several studies that find increased mortal-
ity with high iPTH values; much higher than 300 pg/ml. Thus,
the more  recent KDIGO Guidelines19 defined adequate iPTH as
2–9 times above the normal values. However, not all nephrol-
ogists were  completely convinced with this recommendation.
The recent COSMOS study has found that in a large cohort
of patients followed for 5 years, the PTH values associated
with less mortality are fin the range of 168–674 pg/ml,20 very
similar to the  KDIGO recommendations. The authors of the
COSMOS study recommend modifying the reference values of
PTHi based on bone histomorphometric studies, by PTH values
based on survival. Although there are contradictory results, it
seems that the mortality associated with serum PTH describes
a J shape curve, with higher mortality in patients with lower
and higher PTH values. But there is  also significant variability
between the different PTH 2nd generation commercial kits21
which makes it difficult to interpret the  results.
The variability in PTH measurements poses several prob-
lems when interpreting their values, and deciding the
target values to be achieved when treating a  renal patient.
What would be the normal values?, those based on his-
tomorphometric studies?, the  ones based on mortality?,
both?; which method use to measure the PTH, 2nd or 3rd
generation?
The present study evaluated the differences in mortality
prediction using PTH values obtained with measurement of
2nd and 3rd generation in a group of hemodialysis patients
followed for 2 years. In addition, we  have evaluated the PTH-
bio/PTHi ratio as  a possible marker of mortality, in case the
ratio of the circulating molecules could be  a  marker. In addi-
tion, we have analyzed the association between mortality and
serum iPTH levels recommended by KDOQI (150–300 pg/ml)
and the range obtained by COSMOS (168–674 pg/ml).
So the values of PTH that best predict mortality were
determined.
Material  and  methods
This is a two-year prospective study performed under daily
clinical practice conditions. The main objective of this
study was  to determine the association of serum PTH with
hemodialysis patient survival. It included 145 hemodialysis
patients from a  single center, who  underwent a baseline ana-
lytical determination, followed by a follow-up of two years. We
determined clinical parameters and baseline analysis in which
PTH was determined by 2 different methods, 2nd and 3rd gen-
eration, as  well  as  calcium, phosphorus, alkaline phosphatase
and bone alkaline phosphatase, FGF23, 25  (OH)-vitamin D, and
bone remodeling markers. The values of PTH-intact (PTHi) or
PTH of 2nd generation were determined by an  electrochemi-
luminescence method using the Elecsys autoanalyzer (Roche);
this method uses an antibody directed against amino acids
26–32 of the molecule and another against the aminoacids
55–64. Therefore it does not detect short carboxyterminal
fragments, but this method measures PTH 1–84 and long
PTH fragments 7–84 and amino-PTH11 (intra- and inter-assay
coefficients of variation are  <2.5 and <3% respectively and
sensitivity of 1.2 pg/ml method). The PTHi values were nor-
malized to the Allegro PTHi using the formulas given by the
Spanish Society of Nephrology (SEN). The values of PTH of 3rd
generation or PTH-bio were determined by an  electrochemi-
luminescence method also using the  Elecsys autoanalyzer
(Roche), which uses an antibody directed against amino acids
1–4 of the molecule and another against aminoacids 55–64,
thus measuring the molecule 1–84 and the amino-PTH11
(coefficients of intra- and inter-assay variation are <3 and <6%
respectively and the sensitivity of the method is 5.50 pg/ml).
Normal values of PTHb were defined as  50% of the value of
PTH.15
The ratio of PTHbio/PTHi molecules was also calculated in
order to determine the proportion of PTH fragments 7–84.
A registry of deceased patients (of  any cause) was recorded
at year 1 and 2, and general analytical parameters of mineral
metabolism, inflammation and nutrition were determined. In
both the annual and the two-year follow-up, the PTH was mea-
sured using the 2nd generation method.
The ADVIA CENTAUR 2400 autoanalyzer was used for the
measurements of serum albumin (bromocresol green dye
binding technique; intra- and inter-assay coefficients of vari-
ation were <1.3 and <2% and the sensitivity of the method
was 1 g/dl). Serum calcium (arsenazo III technique, coefficients
of intra- and inter-assay variation are <1.2 and <2%, and the
sensitivity of the method is 0.5 mg/dl), serum creatinine (alka-
line picrate technique, intra- and inter-assay variation are
<3.1 and <4%, and the sensitivity of the method is 0.2 mg/dl),
serum phosphate (UV phosphomolybdate technique; intra-
and interassay coefficients of variation are <2, 2 and <3%,
and the sensitivity of the method is 0.3 mg/dl), total serum
proteins (biuret technique, intra- and inter-assay coefficients
of variation are <1.3 and <2%, and sensitivity of the method
is 2 g/dl), PCR (turbidimetric technique enhanced with latex,
coefficients of intra- and interassay variation are  <4.9 and
<6%, and the sensitivity of the method is 0.003 mg/dl), and
serum alkaline phosphatase (hydrolysis p-nitrophenyl phos-
phate; Coefficients of intra- and interassay variation are <1.9
and <2.4%, and the sensitivity of the method is 5 U/l).
Serum prealbumin values were determined by turbidime-
try in  a SPA plus autoanalyzer, with intra- and interassay
coefficients of variation being <4.4 and <6% respectively and a
sensitivity of 0.006 g/l.
The values of total vitamin D (25 [OH] vitamin D2
and D3) were determined by an  electrochemiluminescence
method performed on the Elecsys autoanalyzer (Roche) with
coefficients of intra- and inter-assay variation respectively
<7.5% and <8% and sensitivity of 3 ng/ml.
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Plasma (C-terminal) fibroblast growth factor 23 (FGF-23)
was determined by an ELISA method (Immutopics, USA) using
2  polyclonal antibodies directed to the  C-terminal fraction of
FGF-23 (coefficients Of intra- and inter-assay variation are <1.7
and <3.5% respectively and the sensitivity of the method is
1.5 RU/ml).
The bone isoenzyme of alkaline phosphatase was deter-
mined in serum by ELISA (OSTASE BAP, IDS, UK) (coefficients of
intra- and inter-assay variation are <4.5 and <6.4% respectively
and the sensitivity of the method is 0.7 Mg/l).
The determination of the C-terminal propeptide of procol-
lagen type I  (PINP) and the -Cross Laps (-CTX) in serum was
performed by electrochemiluminescence in the Elecsys auto-
analyzer (Roche) (for PINP coefficients of intra- and interassay
variation are <2.9 and <3.7% respectively and the sensitivity
of the method is 5  g/l; for -CTX, coefficients of intra- and
interassay variation are <4.6 and <4.7% respectively and sen-
sitivity of the method is 0.07 ng/ml).
Results
A prospective study including 145 hemodialysis patients was
conducted for two  year  period; 49% were women. Table 1
shows baseline clinical and biochemistry data of the patients
studied. 85.1% of the  patients was on some type vitamin D
receptor activator, and 17.9% received cinacalcet.
Twenty one patients died during the first year follow-up,
and 28 in the second year. Potential Clinical and biochemical
variables analytical that correlate with mortality are shown
in Table 2. The parameters related to mortality were albumin,
prealbumin, C-reactive protein, ProBNP, creatinine, age, vas-
cular access type, and bone alkaline phosphatase. However,
the PTH values of both the 2nd (PTHi) and the 3rd generation
(PTHbio) and the ration PTHi/PTHbio of the patients who died
were not different than in patients that remained alive.
The main objective of this study is  to define the effect on
the mortality of PTH values of both 2nd and 3rd generation,
as the ratio between both. Second generation PTH (PTHi) and
third generation PTH (PTHbio) have a good correlation within
each other. The correlations of PTH from 2nd and the  3rd gen-
eration, with other molecules of the mineral metabolism are
similar (Table 3).
The ratio PTHbio/PTHi decreases as  la  PTHi values
increases suggesting that non 1–84 fragments increase sec-
ondary to a  degradation of the PTH 1–84 (Fig. 1).
When patients were stratified by PTH intervals, a signif-
icant increase in mortality was observed in patients with
extreme PTHi values: greater than 678 pg/ml and less than
150 pg/ml, compared to the group of patients with PTH
between 150 and 300 pg/ml (Fig. 2); although the mortality is
higher among patients with PTHi between 300 and 678 pg/ml
than in those whose PTHi is 150–300 pg/ml (Fig. 2), this dif-
ference did not reach statistical significance. With  the PTHbio
calculated as 50% of the PTHi the differences are not signifi-
cant in the same intervals.
Comparison of mortality in the PTH range recom-
mended by the current SEN and KDOQI PTHi guidelines
(150–300 pg/ml) and the values established by the COSMOS
study (164–678 pg/ml) (Table 4), the  relative risk of mortality
Table 1 – Demographic and clinical characteristics; and,
baseline biochemistry of the study population.
Variable
Age  (years) 65.9 ± 14.6
Dry weight (kg) 65.5 ± 14.2
Vintage (years) Mean 3 (P25-2; P75-6)
Males (%)  51
Vascular access (%)
AVF 60.8
PTFE (politetrafluoroetileno) 19.2
Permanent catheter 20
Hemodilalysis technique (%)
Conventional 90
On-line 10
Hypertension (%) 86.9
Diabetes mellitus (%) 23.4
Dyslipemia (%)  35.2
M ± SD
Hemoglobin (g/dl) 11.8 ±  1.6
Hematocrit (%) 35.5 ±  4.6
Urea (mg/dl) 117.7 ±  36.5
Proteins (g/dl) 6.5 ±  0.6
Albumin (g/dl) 3.6 ±  0.4
Iron (g/dl) 65.4 ±  28
Fe saturation index (%)  31.7 ±  14.3
Calcium (mg/dl) 9.2 ±  0.7
Phosphate (mg/dl) 4.7 ±  1.6
CO2 21.4 ±  3.5
Total cholesterol (mg/dl) 158 ±  35
Prealbumin (mg/dl) 33  ±  10
Ferritin (ng/dl) 406 ±  242
Mean (P25;P75)
Bone alkaline phosphatase (g/l) 29.6 (20.7;41.9)
PINP (g/l) 255.3 (161.2;486.6)
-CTX (ng/ml) 1.8  (1.3;2.5)
PTH 2.a gen (iPTH) (pg/ml) 205 (116.5;386.1)
PTH 3.a gen (bioPTH) (pg/ml) 119.5 (76.2; 240
Ratio bioPTH/iPTH 0.61 (0.56;0.68)
25OH- D (ng/dl) 22.9 (12.7;34.2)
Creatinine (mg/dl) 7.6  (5.6;9.1)
Alkaline phosphatase (UI/l) 111 (89;145)
Triglycerides (mg/dl) 146 (102;193)
C reactive protein (mg/dl) 0.6  (0.25;1.97)
ProBNP (pg/ml) 8325 (3422;17450)
FGF-23 (RU/ml) 788 (384;3258)
is  only significant with PTH greater than 300 pg/ml and less
than 150 pg/ml. This implies that patients with PTHi greater
than 300 have higher mortality only when patients with PTHi
greater than 678 pg/ml are included. In our study, iPTH showed
a better predictive value of mortality than bioPTH, taking
150–300 (75–150) pg/ml as  a  reference, but it is due to  the
patients with highest PTH values (Table 4).
No differences were observed in bioPTH/iPTH ratio between
patients who died and those who did not. Likewise, no dif-
ferences in mortality were observed when the PTHbio/PTHi
ratio was analyzed by quintiles, so bioPTH/iPTH ratio does not
appear to be a  marker of mortality (Fig. 3). The bioPTH/iPTH
value higher than 0.8 has a  higher mortality, but given the
small group of patients this difference is not significant.
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Table 2 – Variables significantly related with mortality.
Variable No  exitus Exitus p  value
Age (years) M ± DE 62.8 ± 14;9 73.0 ±  10.6 p < 0.0001
Vintage Me (P25,P75) 3 (2;5.5) 4  (3;7) p = 0.027
Permanent catheter (%) 9.9  36.4 p < 0.0001
Albumin (g/dl) M ±  DE 3.72 ± 0.48 3.51 ±  0.42 p = 0.0138
Prealbmin (mg/dl) M ± DE 35.1 ± 9.6  28.1 ±  10  p = 0.0008
Bone alkaline phosphatase (g/l) Me (P25,P75) 26.8 (19.7;31.7) 31.4 (22.4;45.5) p = 0.037
Creatinine (mg/dl) Me (P25,P75) 8  (5.8;9.8) 6.6  (5.5;8.4) p = 0.018
CRP (mg/dl) Me (P25,P75) 0.25 (0.25;1.37) 1.3  (0.25;3.4) p = 0.0001
ProBNP (pg/ml) Me (P25,P75) 6590  (2778;14450) 14,100  (6580;34000) p = 0.0001
Table 3 – Correlation of PTH 2.a y  3.a generation with other molecules of mineral metabolism.
Variable iPTH bioPTH
r  p r  p
25OH-D (ng/dl) −0.034 ns −0.033  ns
FGF-23 (RU/ml) 0.296 0.0003 0.228  0.006
Alkaline phosphatase (UI/l) 0.268 0.0012 0.254  0.0022
Bone alkaline phosphatase (g/l) 0.342 0.0000 0.338  0.0000
Calcium (mg/dl) −0.001 ns  −0.050 ns
Phosphate (mg/dl) 0.326 0.0001 0.295  0.0003
Table 4 – Mortality in  patients with PTH within reference values established by Guides SEN and KDOQI (150–300 pg/ml)
and COSMOS (168–674 pg/ml) using iPTH and bio PTH methods.
Guides
iPTH
Exitus
No/yes
OR  (IC95%) p Guides
bioPTH
Exitus
No/yes
OR (IC95%) p
150–300 34/8 75–150 24/6
<150 27/19 2.99 (1.14–7.88) 0.024 <75 29/19 2.62 (0.90–7.60) ns
>300 27/20 3.15 (1.20–8.25) 0.017 >150 35/23 2.63 (0.93–7.42) ns
Cosmos
iPTH
Exitus
No/yes
OR (IC95%) p  Cosmos
BioPTH
Exitus
No/yes
OR (IC95%) p
168–674  47/22 84–337 56/27
<168 36/20 1.19 (0.56–2.50) ns <84 25/15 1.24 (0.57–2.74) ns
>674 5/6 2.56 (0.71–9.32) ns >337 7/7 2.07 (0.66–6.51) ns
Discussion
In renal patients, abnormalities of mineral metabolism are
a risk for cardiovascular disease.22 However, among the
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parameters of mineral metabolism PTH has a  relatively low
weight as  a  marker of morbidity and mortality in  the  renal
patient. In our study we  observed that PTH is not a marker
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of greater influence such as  age, years on dialysis, albumin
or vascular access. However, it is an  important modulator of
all alterations of mineral metabolism, so its control should
not be neglected. As we observed, PTHb and PTHi correlate
very well with other parameters such as  phosphorus, FGF23,
bone alkaline phosphatase and years of dialysis. All these
parameters are  associated with morbimortality. In fact, many
research groups find a  greater interest in combining several
parameters of mineral metabolism as  a marker of mortality.9
The main objective of this work  has been to define PTH as a
marker of mortality and the reference values that should used
in daily practice.
The relationship between iPTH and mortality is contro-
versial. Although most studies find that PTHi is  a  marker of
mortality some authors did not.9 The established range of
150–300 pg/ml were based on histomorphometric criteria, but
these values are also the inflection points in mortality. The
meta-analysis of Natoli et  al.8 described PTH related mortal-
ity as a J curve. We  also a J-shaped mortality curve where
values with lower mortality are within the PTHi range of
150–300 pg/ml.
Like other authors,23 we  found a correlation between iPTH
and bioPTH. Thus once adjusted, the  values of normality could
be used interchangeably. In addition, both determinations cor-
relate with the same clinical and analytical parameters, so it
appears that one method does not have an advantage over
the other. It is known that as  the glomerular filtration rate
decreases there is  an increase in non-1–84 fragments.24 It is
remarkable to see that as  the 1–84 PTH increases, the frag-
ments are also increased even to a  greater extent than the
1–84 PTH molecule itself. As  non-1–84 fragments are antago-
nists of 1–84 PTH it could be assumed that at a higher iPTH, the
systemic effects, especially bone, would be reduced by these
molecules. This aspect deserves to be investigated in  order to
know its relevance. The changes in  the proportion of these
fragments are important when defining the normal values of
bioPTH.
However, in  our study we did  not observe that patients with
a low PTHb/PTHI ratio had a  lower mortality due to  an increase
in  the 7–84 fragments, suggesting that the PTH 1–84 molecule
has  a  relevant role in  the mortality of these patients.
The normal values of bioPTH are defined as 54% of iPTHi.15
However, in our study, it was observed that this proportion
varies according to the iPTH values. That is, at higher 1–84
PTH the non-1–84 PTH fragments increase to a greater extent
than the 1–84 PTH itself. Therefore, the normal values of 1–84
PTH measured by 3rd generation methods in the hemodialysis
patient are not known at present, as  they are not yet formally
established in any guideline recommendations. According to
our results, limits of bioPTH should be narrow, since elevations
of 1–84 PTH are accompanied by an even greater proportional
increase non 1–84 PTH fragments; this should be considered
when establishing normal values for bioPTH. It is not known
how to interpret the values of bioPTH after eliminating the
distortion factor of fragments non 1–84 PTH, since there are
no studies to that end. The assumption of bioPTH as 50–54%
of the iPTH does not seem correct, as it does not correspond to
reality. A  multicenter study should be performed with a  large
number of patients to define these values.
The COSMOS study finds that a iPTH of 674 ng/ml may
be  established as the upper limit of the reference interval in
terms of mortality. Like other authors25 we did  not find, that
a  higher mortality in  patients with iPTH between 300 and 674
than in those with iPTH between 150 and 300 ng/ml. These
results should make us cautious before establishing the value
of 678 ng/ml as  the upper reference value. Mortality is signifi-
cant above 678 pg/ml, but we should never consider that figure
as a safe value. Statistical significance should not make us
think that an increase in iPTHi up to  9 times normal values
is  safe. Such a  high iPTH value may  cause alterations of the
mineral metabolism that may  have negative repercussion in
the renal patient. There is  a  confidence zone between 300 and
678 pg/ml in which mortality is low but we  think that being
near 300 is safer than 678 pg/ml.
The bioPTH (1–84)/PTHi (1–84 PTH + non 1–84 PTH) ratio
has been evaluated as a  marker of bone histomorphometric
changes and as a predictor of mortality. However the evidence
is still sparse. Like in the  study by Melamed et al.,15 our results
show that the ratio is not associated with mortality. Other
authors have found that ratio bioPTH/iPTH is a good marker
of mortality in  men  on hemodialysis.26 Those patients with
higher values of ratio bioPTH/iPTH ratio would have a  higher
mortality.
Our study has  several limitations. The sample of patients
studied is small, since a larger group of extreme PTH values
is necessary. Another limitation of our study is to  have per-
formed bio PTH at baseline only and not being repeated in
successive time points.
Conclusions
According to our results the values of PTHi defined by histo-
morphometric criteria are well-established limits of mortality
in hemodialysis patients, the 300 pg/ml value defines better
the cutoff point of mortality than the  674 value defined in the
COSMOS study, although the mortality between 150–300 and
300–678 pg/ml is  the  same. The 3rd generation of PTH mea-
surement method that define the bioPTH do not add more
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precision to define defining mortality. The normal values of
iPTH are not well defined, so the iPTH and bioPTH may not
be compared with the values currently stablished. The ratio
bioPTH/iPTH ratio is  not a  good marker of mortality.
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